An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus

Study identifier:H8O-MC-GWAN

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 3

Healthy volunteers

Study drug

exenatide

Sex

All

Actual Enrollment

275

Study type

Interventional

Age

30 Years - 75 Years

Date

Study Start Date: 01 Dec 2003

Primary Completion Date: 01 Jul 2008

Study Completion Date: 01 Jul 2008

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria

Location

Research Site

Renton, Washington, United States

Arms	Assigned Interventions
Experimental: Group A Exenatide injection 5mcg or 10 mcg, twice daily	Drug: exenatide subcutaneous injection, 5mcg or 10 mcg, twice daily Other Name: Byetta

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center Support Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Chief Medical Officer

Eli Lilly and Company

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Documents available

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator